Новый взгляд на возможности альфа-липоевой кислоты:доказанная клиническая эффективность и перспективы (Обзор литературы)

1. Аметов А.С., Строков И.А. Диабетическая полинейропатия: настоящее и будущее. Российские медицинские вести. 2001; 6 (1): 35–40.
2. Аметов А.С., Строков И.А., Баринов А.Н. и др. Альфа-липоевая кислота в лечении симптомной диабетической полиневропатии: symptomatic diabetic neuropathy (SYDNEY) trial. Фарматека. 2004; 11 (88): 69–73.
3. Афонина Ж.А., Строков И.А., Аметов А.С., Войчик Э.А. Лечение тоннельных невропатий рук у больных сахарным диабетом. РМЖ. 2008; 16 (12): 1621–5.
4. Зотова Е.В., Чистяков Д.А., Савостьянов К.В. и другие. Изучение ассоциации полиморфных маркеров Ala(-9) Val гена SOD2 и Arg213Gly гена SOD3 с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2003; 3: 345–8.
5. Иксанова Г.Р., Сайфуллина Э.И., Колчина Э.М. и др. Использование перфузионнной компьютерной томографии мозга для оценки эффективности берлитиона при ишемическом инсульте. Журн. неврол. и психиат. им. С.С.Корсакова. 2008; 1: 45–50.
6. Ковряжкина Е.А. и др. Возможности и перспективы использования берлитиона в лечении алкогольной полиневропатии. Журн. неврол. и психиат. им. С.С.Корсакова. 2004;104 (2): 33–7.
7. Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М.: Медицина, 2000.
8. Лаврова И.Н. Роль сосудистых и метаболических нарушений в развитии диабетической полиневропатии. Клинико-генетическое исследование. Автореф. дис. … канд. мед. наук. М., 2005.
9. Макеева А.В., Попова Т.Н., Матасова Л.В. и др. Влияние липоевой кислоты на содержание цитрата, активность аконитат гидралазы и оксидативный статус во время ишемии миокарда у крыс. Биохимия. 2008; 73 (1): 76–9.
10. Прихожан В.М. Поражение нервной системы при сахарном диабете. М.: Медицина, 1981.
11. Соловьева Э.Ю., Миронова О.П., Баранова О.А. и др. Свободно-радикальные процессы и антиоксидантная терапия при ишемии мозга. Журн. неврол. и психиат. им. С.С.Корсакова. 2008; 108 (5): 37–42.
12. Стаховская Л.В., Шеховцова К.В., Кербиков О.Б. Антиоксидантная терапия в раннем восстановительном периоде ишемического инсульта (результаты исследования «ПОБЕДА»). Cons. Med. 2009; 1: 27–31.
13. Строков И.А., Аметов А.С., Козлова Н.А., Галеев И.В. Клиника диабетической невропатии. Рус. мед. журн. 1998; 12: 797–801.
14. Строков И.А., Баринов А.Н., Новосадова М.В. и др. Клинические методы оценки тяжести диабетической полиневропатии. Неврологический журнал. 2000; 5: 14–9.
15. Строков И.А., Манухина Е.Б., Бахтина Л.Ю. и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. Бюлл. эксперимент. биол. и мед. 2000; 130 (10): 437–41.
16. Ametov AS, Barinov A, Dyck PJ et al.The sensory symptoms of diabetic polyneuropathy are improved with a-lipoic acid. Diabetes Care 2003; 26 (3): 770–6.
17. Antonio AM, Druse MJ. Antioxidants prevent ethanol-associated apoptosis in fetal rhomencephalic neurons. Brain Res 2008; 1204: 16–23.
18. Bae EH, Lee J, Ma SK et al. Alpha-lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 2009; 24: 2692–700.
19. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009; 8: 416–22.
20. Borcea V, Nourooz-Zadeh J, Wolff SP et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med 1999; 22: 1495–500.
21. Borenshtein D, Ofri R, Werman M et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001; 17: 44–50.
22. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.
23. Cameron NF, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 (Suppl. 2): S31–7.
24. Cho YJ, Um HS, Kang EB et al. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. Int J Mol Med 2010: 25: 337–46.
25. Choi SY, Yu JH, Kim H. Mechanism of alpha-lipoic acid-induced apoptosis of lung cancer cells. Ann N Y Acad Sci 2009; 1171: 149–55.
26. Di Geronimo G, Caccese AF, Caruso L et al. Treatment of carpal tunnel syndrome with alpha-lipoic acid. Eu Rev Med Pharmacol Sci 2009; 13: 133–9.
27. Fermiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 2002; 31: 267–9.
28. Fermiano F, Gombos F, Scully C et al. Burning mouth syndrome (BMS): controlled open trial of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis 2000; 6: 274–7.
29. Fermiano F, Gombos F, Scully C. Burning mouth syndrome (BMS): the efficacy of lipoic acid on subgroups. J Eur Acad Dermatol Venereol 2004; 18: 676–8.
30. Gleiter CH, Schug BS, Hermann R et al. Influence of food intake on the bioavailability of thioctic eneantiomers. Eur J Clin Pharmacol 1996; 50: 513–4.
31. Gur S, Kadowitz PJ, Hellstrom WJ. A critical appraisal of erectile function in animal models of diabetes mellitus. Int J Androl 2009; 32: 93–114.
32. Haak ES, Usadel KH, Kohleisen M et al. The effect of a-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28–34.
33. Hager K, Kenklies M, McAfoose J et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease – a 48 months follow-up analysis. J Neural Transm Suppl 2007; 72: 189–93.
34. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010; 7: 51–61.
35. Hermann R, Niebch G. Human pharmacokinetics of a-lipoic acid. In book «Lipoic acid in health and disease» (Eds. Fuchs J, Packer L, Zimmer G) – Marcel Dekker Inc N-Y 1997; p. 337–60.
36. Hofmann MA, Bierhaus A, Zumbach MS et al. Insufficient glycemic control increases nuclear factor-_B binding activity in peripheral blood mononuclear cells isolated from patients with type I diabetes. Diabetes Care 1998; 21: 1310–6.
37. Holmquist L, Stuchbury G, Berbaum K et al. Lipoic acid as a novel treatment for Alzheimer's desease and related dementias. Pharmacol Ther 2007; 113: 154–64.
38. Jones RE, Moes N, Zwickey H et al. Treatment of experimental autoimmune encephalomyelitis with alpha lipoic acid and associative conditioning. Brain Behav Immun 2008; 22: 538–43.
39. Kang KP, Kim DH, Jung YJ et al. Alpha-lipoic acid attenuates cisplatin-induced acutr kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 2009; 24: 3012–20.
40. Lee WY, Orestes P, Latham J et al. Molecular mechanisms of lipoic acid modulation of T-type calcium channals in pain pathway. J Neurosci 2009; 29: 9500–9.
41. Li C, Zhang Q, Li M et al. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chinese Med J 2009; 122: 2580–6.
42. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: a overview. Neurochem Res 2008; 33: 194–203.
43. Maczurec A, Hager K, Kenklies M et al. Lipoic acid as anti-inflammatory and neuroprotective treatment for Alzheimer's desease. Adv Drug Deliv Rev 2008; 60: 1463–70.
44. Melhem MF, Craven PA, Liachenko J et al. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002; 13: 108–16.
45. Melli G, Tiaana M, Camozzi F et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol 2008; 214: 276–84.
46. Moreira PI, Hamis PL, Zhu X et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 2007; 12: 195-206.
47. Na MH, Seo EY, Kim WK. Effects of alpha-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutr Res Pract 2009; 3: 265–71.
48. Nagamatsu M, Nickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160–7.
49. Nosikov VV, Strokov IA, Nikitin AG et al. Poly (ADP-ribose) polymerase-1 gene (PARP1) involved in the genetic susceptibility to diabetic polyneuropathy in Russian patients with Type 1 diabetes mellitus. In book of abstr. 14th Annual Scientific Meeting of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB) – Regensburg, Germany 2004; p. 138.
50. Packer L, Witt EH, Tritschler H. Alfa-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50.
51. Pouyatos B, Geahart C, Nelson-Miller A et al. Lipoic acid and 6-formylpterin reduse potentiation of noice-induced hearing loss by carbon monoxide: preliminary investigation. J Rehabil Res Dev 2008; 45: 1053–64.
52. Ramrath S, Tritchler HJ, Eckel J. Stimulation of cardiac glucose transport by thioctic acid and insulin. Horm Metab Res 1999; 31: 632–5.
53. Ranieri M, Sciuscio M, Cortese AM et al. The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain: effect on health-related quality of life. Int J Immunopathol Pharmacol 2009; 22 (Suppl. 3): 45–50.
54. Reed LJ. Multienzyme complex. Acc Chem Res 1974; 7: 40–6.
55. Sabharwal AK, May JM. Alpha-lipoic acid and ascorbatr prevent LDL oxidation and oxidant stress in endothelial cell. Mol Cell Biochem 2008; 309: 125–32.
56. Salinthone S, Yadav V, Bourdette DN et al. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflamatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008; 8: 132–42.
57. Salinthone S, Schilliace RV, Marracci GH et al. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits INF gamma synthesis and cellular cytotoxicity in NK cells. J Neuroimmunol 2008; 199: 46–55.
58. Schilliace RV, Pisenti N, Pattamanuch N et al. Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochem Biophys Res Commun 2007; 354: 259–64.
59. Sehirli O, Tatlidede E, Yuksel M et al. Antioxidant effect of alpha-lipoic acid against ethanol-induced gastric mucocal erosion in rats. Pharmacology 2008; 81: 173–80.
60. Senoglu M, Nacitarhan V, Kurutas EB et al. Intraperitoneal alpha-lipoic acid to prevent neural damage after crush injury to the rat sciatic nerve. J Brachial Plex Peripher Nerve Inj 2009; 4: 22.
61. Smith AR, Visioli F, Frei B et al. Lipoic acid significantly restores, in rats, the age-related decline in vasomotion. Br J Pharmacol 2008; 153: 1615–22.
62. Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343–8.
63. Somani SM, Husain K, Whitworth C et al. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 2000; 86: 234-41.
64. Steele JC, Bruse AJ, Drage LA et al. Alpha-lipoic acid treatment of 31 patients with sore, burning mouth. Oral Dis 2008; 14: 529–32.
65. Stevens MJ, Obrosova I, Cao X et al. Effect of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006–15.
66. Strokov IA, Bursa TR, Drepa OI et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol 2003; 40: 375–9.
67. Takumida M, Anniko M. Radical scavengers for elderly patients with age-related hearing loss. Acta Otolaryngol 2009; 129: 36–44.
68. Tardif JC, Rheaume E. Lipoic acid supplementation and endothelial function. Br J Pharmacol 2008; 153: 1587–8.
69. Tharakan B, Hunter FA, Smythe WR et al. Alpha-lipoic acid attenuates hemorragic shock-induced apoptotic signaling and vascular hyperpermeability. Shock 2008; 30: 571–7.
70. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561–8.
71. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
72. Toklu HZ, Hakan T, Biber N et al. The protective effect of alpha lipoic acid against traumatic brain injury in rats. Free Radic Res 2009; 43: 658-67.
73. Uchigata Y, Hirata Y. Insulin autoimmune syndrome. Ann Med Interne (Paris) 1999; 150: 245–53.
74. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compare with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53.
75. Vincent HK, Bourguignon CM, Vincent KR et al. Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study. J Altern Complement Med 2007; 13: 577–84.
76. Ying Z, Kherada N, Farrar B et al. Lipoic acid effects on established atherosclerosis. Life Sci 2010; 86: 95–102.
77. Zhang W, Frey B. a-lipoic acid inhibits TNF- a-induced NF-κB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15: 2423–32.
78. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy. Treat Endocrinol 2004; 3: 1–17.
79. Ziegler D, Ametov A, Barinov A et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
80. Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant a-lipoic acid: a meta-analysis. Diaberic Medicine 2004; 21: 114–21.
81. Ziegler D, Reljanovic M, Mehnert H et al. a-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107: 421–30.
82. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant a-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425–33.